Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGalliford Try Regulatory News (GFRD)

Share Price Information for Galliford Try (GFRD)

Share Price is delayed by 15 minutes
Get Live Data
522.00    -3.00 (-0.57%)
Bid:
524.00
Ask:
526.00
Spread: 2.00 (0.382%)
Market Cap: £512.62m
GFRD Live PriceLast checked at - London Stock Exchange

Intraday Galliford Try Share Chart

Contract

24 Sep 2019 07:00

RNS Number : 3679N
Galliford Try PLC
24 September 2019
 

GALLIFORD TRY APPOINTED TO HIGHWAYS PROJECTS VALUED AT £461M

 

Galliford Try plc, the leading housebuilding, regeneration and construction group, announces its Highways business has been appointed to new projects valued at a total of £461m.

 

The largest of the schemes is a series of five projects in the eastern region valued at £300m to upgrade the A47 between Great Yarmouth and Peterborough. Work includes dualling single carriageways, road widening and construction of new junctions, bridges and other structures. Start on site is anticipated to be in 2021/22.

 

The other major scheme with an overall value of £135m is located in the south-west region on the A303 between Sparkford and Ilchester in Somerset. Work includes dualling 5.6km of the existing single carriageway, three new junctions, two new structures and significant earthworks. Subject to planning consent, start on site is due next March with the new route open to traffic in 2023.

 

Both schemes have been awarded by Highways England under the new Regional Delivery Partnerships Framework. The appointments include an initial design phase before moving on to construction.

 

Additionally, Galliford Try has been awarded phase two of Grantham Southern Relief Road by Lincolnshire County Council. The £19m project will join the B1174 to the A1 via a grade separated junction.

 

Finally, Leicestershire County Council has awarded the business the £7m contract to carry out improvements to the A46 and A5630 at Anstey to increase capacity for a new housing and industrial development in the north-west of Leicester.

 

Graham Prothero, Chief Executive of Galliford Try plc, commented: "The Highways sector is a key strategic focus for our construction business as set out in our recent results, and we are delighted to have secured this high-quality pipeline of work. We have a strong working relationship with Highways England and the county councils involved and we look forward to delivering these much-needed infrastructure improvements alongside them."

 

 

For further enquiries please contact:

 

Galliford Try

 

Graham Prothero, Chief Executive 01895 855001

Andrew Duxbury, Finance Director

Kevin Corbett, General Counsel & Company Secretary

 

Galliford Try plc is a leading UK housebuilding, regeneration and construction group. It is listed on the London Stock Exchange and a member of the FTSE 250. Housebuilding - through our Linden Homes business - develops private and affordable homes in prime locations. Galliford Try Partnerships - our regeneration business - delivers mixed-tenure solutions working with housing association, local authority and private sector partners. Operating as Galliford Try and Morrison Construction, our Construction business carries out building and infrastructure with clients in the public, private and regulated sectors. At the end of the last financial year to 30 June 2019, the Group generated revenue of £2.8bn.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
CNTDXLFLKKFFBBZ
Date   Source Headline
12th Oct 20227:00 amRNSTransaction in Own Shares
11th Oct 20227:00 amRNSTransaction in Own Shares
10th Oct 20224:00 pmRNSAnnual Financial Report
7th Oct 20224:00 pmRNSDirector/PDMR Shareholding
7th Oct 20227:00 amRNSTransaction in Own Shares
4th Oct 20227:00 amRNSTotal Voting Rights
3rd Oct 20227:00 amRNSTransaction in Own Shares
30th Sep 20227:00 amRNSTransaction in Own Shares
29th Sep 20227:00 amRNSTransaction in Own Shares
28th Sep 20225:30 pmRNSDirector/PDMR Shareholding
28th Sep 20227:00 amRNSTransaction in Own Shares
27th Sep 20225:03 pmRNSDirector/PDMR Shareholding
26th Sep 20227:00 amRNSTransaction in Own Shares
23rd Sep 20224:45 pmRNSDirector/PDMR Shareholding
23rd Sep 20227:00 amRNSTransaction in Own Shares
22nd Sep 20223:00 pmRNSEmployee Share Trust Trading Plan
22nd Sep 20227:00 amRNSTransaction in Own Shares
21st Sep 20227:01 amRNSLaunch of Share Buyback Programme
21st Sep 20227:00 amRNSFinal Results
1st Aug 20227:00 amRNSContract
14th Jul 20227:00 amRNSTrading Statement
11th Jul 20227:00 amRNSAcquisition of MCS Control Systems
1st Jul 202211:00 amRNSDirector Declaration
23rd Jun 20227:00 amRNSContract
31st May 20227:00 amRNSTotal Voting Rights
30th May 202210:00 amRNSExercise of share options
10th May 20227:00 amRNSBusiness Briefing
26th Apr 20227:00 amRNSAppointment of Director
1st Apr 20229:10 amRNSConfirmation of Directorate Change
15th Mar 20227:00 amRNSDirectorate Change
4th Mar 20225:03 pmRNSHolding(s) in Company
3rd Mar 20227:00 amRNSHalf-year Results
9th Feb 20227:00 amRNSContract
19th Jan 20227:00 amRNSTrading Update
31st Dec 202112:36 pmRNSPrice Monitoring Extension
23rd Dec 20214:36 pmRNSPrice Monitoring Extension
21st Dec 202111:51 amRNSDirector/PDMR Shareholding
9th Dec 20217:00 amRNSContract
12th Nov 20214:01 pmRNSResult of AGM
12th Nov 20217:00 amRNSAGM Statement
7th Oct 20213:23 pmRNSAcquisition
7th Oct 202110:27 amRNSDirector Declaration
6th Oct 20217:00 amRNSContract
5th Oct 20214:47 pmRNSAnnual Financial Report
23rd Sep 20214:00 pmRNSDirector/PDMR Shareholding
23rd Sep 20214:00 pmRNSDirector/PDMR Shareholding
17th Sep 20211:00 pmRNSEmployee Share Trust Trading Plan
16th Sep 20217:00 amRNSFinal Results
26th Aug 20213:42 pmRNSHolding(s) in Company
16th Aug 202110:42 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.